Case number 1:22-cv-00439
Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 18, 2022 | 24 | SO ORDERED re (23 in 1:22-cv-00439-MN, 17 in 1:22-cv-01291-MN) Stipulation and Order Regarding Case Consolidation. Signed by Judge Maryellen Noreika on 11/18/2022. (dlw) (Entered: 11/18/2022) (3) |
| Nov 17, 2022 | 23 | STIPULATION Regarding Consolidation, Case Schedule, and Protective Order, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/17/2022) (3) |
| Nov 10, 2022 | 22 | STIPULATION Seeking to Extend the Deadline by Which the Parties in the Non-Consolidated Cases Must Inform the Court Whether they Agree to be Consolidated With, and Adopt the Schedule of the Lead Case, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/10/2022) (5) |
| Oct 19, 2022 | 21 | ORAL ORDER RESETTING Teleconference - IT IS HEREBY ORDERED that the 10/24/2022 teleconference is RESET for 11/3/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/19/2022. (dlw) (Entered: 10/19/2022) (0) |
| Oct 14, 2022 | 20 | NOTICE OF SERVICE of Neurocrine Biosciences, Inc.'s First Set of Requests to Defendants for the Production of Documents and Things (Nos. 1-41) filed by Neurocrine Biosciences, Inc..(Mayo, Andrew) (Entered: 10/14/2022) (4) |
| Oct 6, 2022 | 19 | ORAL ORDER Setting Teleconference: IT IS HEREBY ORDERED that a Telephone Conference is set for 10/24/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/6/2022. (dlw) (Entered: 10/06/2022) (0) |
| Aug 1, 2022 | 15 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, Affirmative Defenses by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC.(Bilson, David) Modified on 8/1/2022 (dlw). |
| Aug 1, 2022 | 16 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Zydus Lifesciences Limited. (Bilson, David) |
| Aug 1, 2022 | 17 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zydus Lifesciences Limited for Zydus Worldwide DMCC filed by Zydus Worldwide DMCC. (Bilson, David) |
| Aug 1, 2022 | 18 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zydus Lifesciences Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Bilson, David) |
| Jul 28, 2022 | 14 | Redacted Document (5) Docket Text: REDACTED VERSION of [12] Stipulation by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC. (Phillips, John) |
| Jul 22, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: D.I. 13 has been placed UNDER SEAL. (dlw) |
| Jul 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [11] STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Complaint (D.I. 1) to August 2, 2022 (Set/Reset Answer Deadlines: Zydus Healthcare (USA) LLC answer due 8/2/2022; Zydus Worldwide DMCC answer due 8/2/2022). ORDERED by Judge Maryellen Noreika on 7/19/2022. (dlw) |
| Jul 19, 2022 | 11 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendants to answer, move or otherwise respond to Complaint (D.I. 1) to August 2, 2022 - filed by Zydus Healthcare (USA) LLC, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC. (Phillips, John) |
| Jun 30, 2022 | 7 | Affidavit of Service (1) Docket Text: AFFIDAVIT of Service for Summons, Complaint, and related documents served on Zydus Healthcare (USA) LLC on 6/28/2022, filed by Neurocrine Biosciences, Inc.. (Mayo, Andrew) |
| Jun 30, 2022 | 8 | Affidavit of Service (1) Docket Text: AFFIDAVIT of Service for Summons, Complaint, and related documents served on Zydus Worldwide DMCC on 6/28/2022, filed by Neurocrine Biosciences, Inc.. (Mayo, Andrew) |
| Jun 30, 2022 | 9 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Zydus Pharmaceuticals (USA) Inc. waiver sent on 6/21/2022, answer due 8/22/2022. (Mayo, Andrew) |
| Jun 30, 2022 | 10 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Zydus Lifesciences Limited waiver sent on 6/21/2022, answer due 8/22/2022. (Mayo, Andrew) |
| Apr 6, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Apr 5, 2022 | 6 | Transcript (20) Docket Text: Official Transcript of Teleconference held on 04/04/2022 before Judge Maryellen Noreika. Court Reporter/Transcriber Dale C. Hawkins,Email: Dale_Hawkins@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/26/2022. Redacted Transcript Deadline set for 5/6/2022. Release of Transcript Restriction set for 7/5/2022. (dh) |
| Apr 1, 2022 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (twk) |
| Apr 1, 2022 | 1 | Main Document (67) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against Zydus Healthcare (USA) LLC, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3841264.) - filed by Neurocrine Biosciences, Inc.. (Attachments: # (1) Exhibit A-Q, # (2) Civil Cover Sheet)(twk) |
| Apr 1, 2022 | 1 | Exhibit A-Q (615) |
| Apr 1, 2022 | 1 | Civil Cover Sheet (3) |
| Apr 1, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Apr 1, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: February 21, 2022. Date of Expiration of Patents: See attached. Hatch-Waxman Regulatory Exclusivity Deadline: October 11, 2024.(twk) |
| Apr 1, 2022 | 4 | Patent/Trademark Report to Commissioner (4) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997; 10,993,941; 11,026,931; 11,026,939; 11,040,029. (twk) |
| Apr 1, 2022 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc. (twk) |
| Apr 1, 2022 | 1 | Complaint* (1) |
